Aarti Pharmalabs Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/6zl9w93f4xsdsmpgciwj0fbn.pdf

Key Takeaways


CDMO/CMO: The Pipeline Is Building, Revenue Is Lumpy

Rashesh Gogri: "Yes, the Biosecure Act has forced US companies to shift away from China, and that's why other non-Chinese suppliers of these intermediates and the GMP intermediates are seeing more inquiries, and we are benefiting from this."

Xanthine: Volume Resilience, Price Pressure

Hetal Gogri Gala: "China is as aggressive as ever, and the pricing have been reduced in the spot market, so we have a balance of contract and spot. So, it is challenging for the spot business. China is becoming very aggressive still."

Margins: The Mix Story


Capacity Expansion: Three Projects, On Schedule

ProjectStatusTimeline
Vapi USFDA Intermediate unitSemi-commercial block production in final stages; smaller reactor block (50L-2KL) commissioned this quarter for early-phase/validation workFully operational Q2 FY25
Atali sitePhase one adding 400-500 KL capacity (25%-30% increase); envisage building similar block or 250-300 KL capacities every yearCommission Q4 FY25
Xanthine capacity expansionBrownfield expansion from 5,000 to 9,000 MT; adjacent land being acquiredComplete beginning of FY26
Solar projectOn verge of completion; estimated to generate one-third of power requirement and reduce overall manufacturing costCommission current quarter

Subsidiaries & Disclosures


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA growthApproximately 10% to 12% growthFY25
CDMO/CMO revenue growthAround +25% over FY24 base of ~₹170 crFY25
Long-term annual growthAround 15%Next several years
Vapi unit fully operationalSemi-commercial block to full operationsQ2 FY25
Atali site commissioningPhase one, 400-500 KL capacityQ4 FY25
Xanthine capacity expansion5,000 to 9,000 MTBeginning of FY26
Solar project commissioningOne-third of power requirementCurrent quarter
Ganesh Polychem separate disclosureRevenue and EBITDA in quarterly resultsFrom next quarterly results

Key Metrics

MetricQ1 FY25
Consolidated revenue₹556 cr, +14% YoY
Standalone revenue₹394 cr
Consolidated EBITDA₹65.3 cr, +18% YoY
Consolidated PAT₹555 cr, +27% YoY
Standalone gross margin48%, vs 54% in Q4 FY24 and 50–52% guidance
Standalone EBITDA margin22%, within 21–23% range
CDMO/CMO revenue contribution2.4% of standalone turnover, down from 18% in Q4 FY24
CDMO/CMO FY25 growth guidance25–30% over FY24 base of ~₹170 cr
Xanthine derivatives revenue contribution54% of turnover
Xanthine derivatives revenue₹210 cr, vs ~₹180 cr in prior 5–6 quarters
Xanthine export share57% of Xanthine revenue
Xanthine spot pricing decline15–20% YoY
API and intermediates revenue contribution44% of turnover; regulated markets 55%, rest of world 35%, non-regulated 10%
CDMO/CMO active projects53 projects, up from ~40 previously, with 18 customers
CDMO/CMO commercial-stage projects27, up from 16 in Q1 FY24 and 21 in Q4 FY24
Overall capacity utilization85% (combined API, intermediates, CDMO/CMO)
FY25 capex outlay~₹500 cr, comprising Atali ~₹375 cr, Xanthine ~₹150 cr (partially in FY25), solar ~₹90 cr